GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (OSTO:ACE) » Definitions » Additional Paid-In Capital

Ascelia Pharma AB (OSTO:ACE) Additional Paid-In Capital : kr678.75 Mil(As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascelia Pharma AB Additional Paid-In Capital?


Ascelia Pharma AB's quarterly additional paid-in capital stayed the same from Sep. 2023 (kr678.75 Mil) to Dec. 2023 (kr678.75 Mil) and stayed the same from Dec. 2023 (kr678.75 Mil) to Mar. 2024 (kr678.75 Mil).

Ascelia Pharma AB's annual additional paid-in capital declined from Dec. 2021 (kr678.83 Mil) to Dec. 2022 (kr678.75 Mil) but then stayed the same from Dec. 2022 (kr678.75 Mil) to Dec. 2023 (kr678.75 Mil).

Ascelia Pharma AB Additional Paid-In Capital Historical Data

The historical data trend for Ascelia Pharma AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascelia Pharma AB Additional Paid-In Capital Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 405.06 493.73 678.83 678.75 678.75

Ascelia Pharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 678.75 678.75 678.75 678.75 678.75

Ascelia Pharma AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Ascelia Pharma AB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Ascelia Pharma AB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascelia Pharma AB (OSTO:ACE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (OSTO:ACE) » Definitions » Additional Paid-In Capital
Comparable Companies
XSAT:CESSA OSTO:NXTCL OSTO:LIPUM OSTO:SIMRIS B OSTO:BIOVIC B OSTO:ALZ OSTO:ZICC OSTO:ELIC NGM:GTAB B OSTO:XINT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
7ZA:Germany
Address
Hyllie Boulevard 34, Malmo, SWE, SE-215 32
Website
https://www.ascelia.com
Ascelia Pharma AB is an oncology-dedicated drug development company located in Malmo, Sweden, focused on the development of novel drugs to improve the life expectancy and quality of life for people living with cancer. The company is focused on two clinical-stage product candidates under development: Mangoral and Oncoral.

Ascelia Pharma AB (OSTO:ACE) Headlines

No Headlines